Abstract
Dramatic progress in therapeutic strategies for malignant tumors and autoimmune diseases has been made recently through the development of monoclonal antibodies targeting various molecules of the immune system. These targets include cytokines, receptors, and other cell surface molecules. Furthermore, there are various candidate diseases in the dermatological field that may be suitable for treatment by immunotherapy. Several immunotherapies are currently in clinical trials in patients with psoriasis vulgaris or autoimmune diseases.
